AtaiBeckley said to explore sale or partnership for its phase 3 nasal spray psychedelic drug BPL-003 for severe depression

AtaiBeckley is working with advisers to explore options for its flagship psychedelic drug candidate, BPL-003, a nasal spray for severe depression entering phase 3 trials. The company is considering a potential sale or partnership and is aiming to secure at least $2 billion from a deal. Jefferies Financial Group and JPMorgan Chase have been selected to lead discussions with other pharmaceutical companies, based on people familiar with the matter.